Brand Name :
Urecholine, Duvoid
Synonyms :
bethanechol
Class :
Cholinergic Agonist, Genitourinary Agent
Brand Name :
Urecholine, Duvoid
Synonyms :
bethanechol
Class :
Cholinergic Agonist, Genitourinary Agent
Dosage Forms & Strengths
Tablet
5mg
10mg
25mg
50mg
10 - 50
mg
Orally
once a day
or divided 3-4 times a day
Take 2 hours after meals or 1 hour before meals
gastro esophageal reflux disease (GERD)
Off-label: 25 mg orally once a day or divided 3-4 times a day
Take 2 hours after meals or 1 hour before meals
10 - 50
mg
Orally
thrice a day
50-100 mg orally twice a day may be needed for certain patients
Take 1 hour before the meals or 2 hours later the meal
gastroesophageal Reflux Disease (GERD)
25mg orally four times a day. Take 1 hour before the meals or 2 hours later the meal
Dosage Forms & Strengths
Tablet
5mg
10mg
25mg
50mg
Off-label: 0.3-0.6 mg/kg orally once a day or divided 3-4 times a day
Take 2 hours after meals or 1 hour before meals
gastro esophageal reflux disease (GERD)
Off-label: 0.3-0.6 mg/kg orally once a day or divided 3-4 times a day
Take 2 hours after meals or 1 hour before meals
0.3 to 0.6 mg/kg/day orally every 6 to 8 hours
Take 1 hour before the meals or 2 hours later the meal
gastroesophageal Reflux Disease (GERD)
0.3 to 0.6 mg/kg/day orally every 6 to 8 hours
Take 1 hour before the meals or 2 hours later the meal
Refer adult dosing
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the toxic effect of cholinergic agonists
may increase the toxic effect of cholinergic agonists
may increase the toxic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
it may increase the risk of adverse effects of cholinergic agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may decrease the toxic effect of beta blockers
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may increase the toxic effect of anti-cholinergic agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
Actions and Spectrum:
Frequency not defined
Belching
Bronchial constriction
Flushing
Headache
Lacrimation
Nausea
Salivation
Abdominal cramps
Borborygmi colicky pain
Diarrhea
Increased gastric motility
Hypotension
Miosis
Vomiting
Urinary urgency
Contraindications/caution:
Contraindications:
Caution:
Pregnancy consideration: C
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
bethanechol is a cholinergic agonist that acts primarily on muscarinic receptors. When administered, bethanechol binds to and activates muscarinic receptors in various smooth muscle tissues, including the bladder and gastrointestinal tract. This leads to increased contractions and enhanced motility in these organs
Pharmacodynamics:
The pharmacodynamics of bethanechol is based on its ability to activate muscarinic receptors in various smooth muscle tissues. When bethanechol binds to muscarinic receptors, it causes the following effects:
Pharmacokinetics:
Absorption
bethanechol is well-absorbed after oral administration, with peak plasma concentrations reached within 60-90 minutes. However, its bioavailability is low, ranging from 5-25%, due to extensive first-pass metabolism in the liver.
Distribution
bethanechol has a low volume of distribution, indicating that it is primarily confined to the extracellular fluid. It does not readily cross the blood-brain barrier.
Metabolism
Acetylcholinesterase primarily metabolizes bethanechol in the liver, hydrolyzing it to its inactive metabolite, choline. It has a relatively short half-life of approximately 1.5 hours.
Elimination and Excretion
bethanechol and its metabolites are primarily excreted in the urine, with approximately 50-60% of a dose eliminated within 24 hours. It is not known to undergo significant enterohepatic circulation.
Administration:
Oral administration:
Administer the medication two hours before or after a meal
Patient information leaflet
Generic Name: bethanechol
Pronounced: [ be-THAN-e-chol ]
Why do we use bethanechol?
bethanechol is primarily used to treat urinary retention and certain gastrointestinal motility disorders. Here are some of the specific uses of bethanechol: